CN110520110A - 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂 - Google Patents

包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂 Download PDF

Info

Publication number
CN110520110A
CN110520110A CN201880021866.7A CN201880021866A CN110520110A CN 110520110 A CN110520110 A CN 110520110A CN 201880021866 A CN201880021866 A CN 201880021866A CN 110520110 A CN110520110 A CN 110520110A
Authority
CN
China
Prior art keywords
brigatinib
pharmaceutical composition
tablet
phenyl
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880021866.7A
Other languages
English (en)
Chinese (zh)
Inventor
当特尔·S·费韦斯
萨米尔·德赛
普拉迪普·K·夏尔马
L·W·罗扎马斯
杰夫·威廉姆森
达尼卡·卡特赖特
帕拉格·韦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Arai Judd Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arai Judd Pharmaceuticals filed Critical Arai Judd Pharmaceuticals
Publication of CN110520110A publication Critical patent/CN110520110A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880021866.7A 2017-03-08 2018-03-06 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂 Pending CN110520110A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762468696P 2017-03-08 2017-03-08
US62/468,696 2017-03-08
US201762491179P 2017-04-27 2017-04-27
US62/491,179 2017-04-27
US201762569954P 2017-10-09 2017-10-09
US62/569,954 2017-10-09
PCT/US2018/021128 WO2018165145A1 (en) 2017-03-08 2018-03-06 Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine

Publications (1)

Publication Number Publication Date
CN110520110A true CN110520110A (zh) 2019-11-29

Family

ID=61750531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880021866.7A Pending CN110520110A (zh) 2017-03-08 2018-03-06 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂

Country Status (7)

Country Link
US (5) US20180256610A1 (https=)
EP (1) EP3592338A1 (https=)
JP (2) JP2020510027A (https=)
CN (1) CN110520110A (https=)
CA (1) CA3055109A1 (https=)
TW (1) TWI794214B (https=)
WO (1) WO2018165145A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115154473A (zh) * 2022-08-04 2022-10-11 中国人民解放军陆军特色医学中心 布格替尼作为axl、c-met、st3gal4抑制剂的新应用
CN115484937A (zh) * 2020-04-14 2022-12-16 詹森生物科技公司 用于口服的包含氨基嘧啶衍生物或其药学上可接受的盐、水合物或溶剂化物的药物组合物
CN116407512A (zh) * 2021-12-31 2023-07-11 南京艾德凯腾生物医药有限责任公司 一种布格替尼冻干口崩片及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094079A1 (en) * 2018-03-19 2019-09-26 Ariad Pharmaceuticals, Inc. Methods of treating cancer in pediatric patients
EP4306115A4 (en) * 2021-07-05 2024-11-20 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition, and preparation method therefor and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143389A1 (en) * 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
CN103153064A (zh) * 2010-10-14 2013-06-12 阿里亚德医药股份有限公司 抑制egfr导致的癌症中细胞增殖的方法
CN103858011A (zh) * 2011-05-23 2014-06-11 细胞信号科技公司 肺癌中的ros激酶
CN104302767A (zh) * 2011-12-10 2015-01-21 俄亥俄州国家创新基金会 用于减少肺癌肿瘤发生和化学疗法抗性的MiRNA以及相关组合物和方法
CN105061506A (zh) * 2015-07-27 2015-11-18 苏州明锐医药科技有限公司 抗肿瘤药物ap26113的制备方法
CN105073116A (zh) * 2013-03-14 2015-11-18 辉瑞大药厂 治疗非小细胞肺癌的egfr t790m 抑制剂与egfr 抑制剂的组合
WO2016065028A1 (en) * 2014-10-21 2016-04-28 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092260A2 (fr) * 2009-02-13 2010-08-19 Ipsen Pharma S.A.S. Compositions pharmaceutiques du 6-oxo-6.7.8,9.10.11-hexahydrocyclohepta mchromen-3-yl sulfamate
US8691281B2 (en) * 2009-02-13 2014-04-08 Ipsen Pharma S.A.S. Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (C)chromen-3-yl sulfamate and polymorphs thereof
WO2013008253A2 (en) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Imatinib formulations
TWI589576B (zh) * 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
LT2753312T (lt) * 2011-09-08 2017-01-25 Mereo Biopharma 2 Limited Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui
AU2012339753A1 (en) * 2011-11-14 2014-06-19 Tesaro, Inc. Modulating certain tyrosine kinases
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
US9474761B2 (en) * 2014-06-10 2016-10-25 The George Washington University Use of NK-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with EGFR-blocking drugs
US10813935B2 (en) * 2017-02-23 2020-10-27 Transgenex Nanobiotech, Inc. Methods and compositions for treating drug resistance in cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143389A1 (en) * 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
CN103153064A (zh) * 2010-10-14 2013-06-12 阿里亚德医药股份有限公司 抑制egfr导致的癌症中细胞增殖的方法
CN103858011A (zh) * 2011-05-23 2014-06-11 细胞信号科技公司 肺癌中的ros激酶
CN104302767A (zh) * 2011-12-10 2015-01-21 俄亥俄州国家创新基金会 用于减少肺癌肿瘤发生和化学疗法抗性的MiRNA以及相关组合物和方法
CN105073116A (zh) * 2013-03-14 2015-11-18 辉瑞大药厂 治疗非小细胞肺癌的egfr t790m 抑制剂与egfr 抑制剂的组合
WO2016065028A1 (en) * 2014-10-21 2016-04-28 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
CN105061506A (zh) * 2015-07-27 2015-11-18 苏州明锐医药科技有限公司 抗肿瘤药物ap26113的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
屠锡德等: "《药剂学》", 31 December 2002, 人民卫生出版社 *
谢秀琼主编: "《现代中药制剂新技术》", 30 April 2004, 化学工业出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115484937A (zh) * 2020-04-14 2022-12-16 詹森生物科技公司 用于口服的包含氨基嘧啶衍生物或其药学上可接受的盐、水合物或溶剂化物的药物组合物
CN116407512A (zh) * 2021-12-31 2023-07-11 南京艾德凯腾生物医药有限责任公司 一种布格替尼冻干口崩片及其制备方法
CN115154473A (zh) * 2022-08-04 2022-10-11 中国人民解放军陆军特色医学中心 布格替尼作为axl、c-met、st3gal4抑制剂的新应用
CN117045664A (zh) * 2022-08-04 2023-11-14 中国人民解放军陆军特色医学中心 布格替尼作为st3gal4抑制剂的新应用

Also Published As

Publication number Publication date
US20210186994A1 (en) 2021-06-24
EP3592338A1 (en) 2020-01-15
US20240082275A1 (en) 2024-03-14
CA3055109A1 (en) 2018-09-13
JP2023027312A (ja) 2023-03-01
US20210401860A1 (en) 2021-12-30
US20180256610A1 (en) 2018-09-13
JP2020510027A (ja) 2020-04-02
TWI794214B (zh) 2023-03-01
TW201840320A (zh) 2018-11-16
WO2018165145A1 (en) 2018-09-13
US20220249524A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
US20240082275A1 (en) Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
JP6560289B2 (ja) 新たな医薬組成物
JP4868695B2 (ja) 崩壊性が良好な経口製剤
JP6396980B2 (ja) ベンダムスチンの固体投与剤
CN107613978B (zh) Mek抑制剂的药物组合物及其制备方法
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
EP3616696B1 (en) Orally administrable enzalutamide-containing pharmaceutical composition
WO2020216274A1 (zh) 一种tlr7激动剂的固体药物组合物
US20100252949A1 (en) Process for Preparing Pramipexole Dihydrochloride Tablets
CA2599649C (en) Drug formulations having controlled bioavailability
JP7264711B2 (ja) レベチラセタム含有医薬組成物の製造方法
EP2672959A1 (en) Granulated composition comprising tadalafil and a disintegrant
CN106994121A (zh) 一种用于治疗癌症的药物组合物
HK40017242A (en) Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine
WO2014157603A1 (ja) 経口投与用医薬組成物
JP2022151857A (ja) エドキサバン口腔内崩壊錠
WO2025226228A1 (en) A novel formulation for palbociclib tablet
TW202404585A (zh) 含有匹密特匹（Pimitespib）之醫藥組合物
JP6668666B2 (ja) イルベサルタンを含有する医薬組成物及びその製造方法
CN121221606A (zh) 化合物及其盐的药物组合物
TW202333702A (zh) 具有優異溶出性之醫藥組成物
HK40105586A (zh) 包含依那格列净的药物组合物
HK40060520B (zh) 一种tlr7激动剂的固体药物组合物
CN114948968A (zh) 一种稳定的三水合盐酸伐地那非药物组合物
HK40025159B (en) Orally administrable enzalutamide-containing pharmaceutical composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017242

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20211110

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: ARIAD PHARMACEUTICALS, Inc.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20191129

RJ01 Rejection of invention patent application after publication